- Home
- TRV vs EW Comparison
TRV vs EW Comparison
Compare TRV & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRV | EW |
|---|---|---|
| Founded | 1853 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8B | 49.5B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TRV | EW |
|---|---|---|
| Price | $278.34 | $84.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $303.75 | $96.79 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 01-21-2026 | 02-10-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 27.43 | 2.33 |
| Revenue | ★ $48,828,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | N/A | $14.35 |
| Revenue Next Year | $4.00 | $9.73 |
| P/E Ratio | ★ $10.15 | $36.24 |
| Revenue Growth | 5.18 | ★ 10.60 |
| 52 Week Low | $230.43 | $65.94 |
| 52 Week High | $296.85 | $87.89 |
Technical Indicators
Market Signals| Indicator | TRV | EW |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 49.04 |
| Support Level | $268.00 | $82.82 |
| Resistance Level | $275.61 | $84.55 |
| Average True Range (ATR) | 5.80 | 1.90 |
| MACD | -1.02 | -0.09 |
| Stochastic Oscillator | 44.66 | 58.05 |
Price Performance
Historical ComparisonAbout TRV The Travelers Companies Inc.
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.